Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2005; 93(01): 178-179
DOI: 10.1055/s-0037-1616162
DOI: 10.1055/s-0037-1616162
Letters to the Editor
Thrombin activatable fibrinolysis inhibitor antigen could not be detected in cerebrospinal fluid
Further Information
Correspondence to:
Jovan P. Antovic, MD, PhD
Coagulation Research
Clinical Chemistry
L25 Karolinska University Hospital
S-171 76 Stockholm, Sweden
Phone: +46 8 517 79653
Fax: +46 8 31 24 28
Email: jovanantovic@yahoo.com
Publication History
Received
01 June 2004
Accepted after resubmission
07 September 2004
Publication Date:
15 December 2017 (online)
MissingLinkText
-
References
- 1 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1477-84.
- 2 Wang W, Boffa MB, Bajzar L. et al A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
- 3 Mosnier LO, von dem Borne PA, Meijers JC. et al Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
- 4 Mosnier LO, Buijtenhuijs P, Marx PF. et al Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
- 5 Antovic JP. Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis. Clin Lab 2003; 49: 475-86.
- 6 Antovic JP, Yngen M, Östenson CG. et al Thrombin activatable fibrinolysis inhibitor (TAFI) and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications Blood Coag Fibrinolysis. 2003; 14: 551-6.
- 7 Bouma BN, Marx PF, Mosnier LO. et al Thrombin- activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
- 8 Wang W, Hendriks DF, Scharpe SS. Carboxy-peptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
- 9 Valnickova Z, Thogersen I B, Christensen S. et al Activated human plasma carboxypeptidase B is retained in the blood by binding to α 2 -macroglobulin and pregnancy zone protein. J Biol Chem 1996; 271: 12937-12943.
- 10 Fareed J, Callas DD, Hoppensteadt D. et al Tissue factor antigen levels in various biological fluids. Blood Coagul Fibrinolysis. 1995; 6 (Suppl. 01) S32-6.
- 11 Suzuki M, Kudo A, Otawara Y. et al Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery 1999; 44: 487-93.
Correspondence to:
Jovan P. Antovic, MD, PhD
Coagulation Research
Clinical Chemistry
L25 Karolinska University Hospital
S-171 76 Stockholm, Sweden
Phone: +46 8 517 79653
Fax: +46 8 31 24 28
Email: jovanantovic@yahoo.com
-
References
- 1 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1477-84.
- 2 Wang W, Boffa MB, Bajzar L. et al A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
- 3 Mosnier LO, von dem Borne PA, Meijers JC. et al Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
- 4 Mosnier LO, Buijtenhuijs P, Marx PF. et al Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
- 5 Antovic JP. Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis. Clin Lab 2003; 49: 475-86.
- 6 Antovic JP, Yngen M, Östenson CG. et al Thrombin activatable fibrinolysis inhibitor (TAFI) and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications Blood Coag Fibrinolysis. 2003; 14: 551-6.
- 7 Bouma BN, Marx PF, Mosnier LO. et al Thrombin- activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
- 8 Wang W, Hendriks DF, Scharpe SS. Carboxy-peptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
- 9 Valnickova Z, Thogersen I B, Christensen S. et al Activated human plasma carboxypeptidase B is retained in the blood by binding to α 2 -macroglobulin and pregnancy zone protein. J Biol Chem 1996; 271: 12937-12943.
- 10 Fareed J, Callas DD, Hoppensteadt D. et al Tissue factor antigen levels in various biological fluids. Blood Coagul Fibrinolysis. 1995; 6 (Suppl. 01) S32-6.
- 11 Suzuki M, Kudo A, Otawara Y. et al Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery 1999; 44: 487-93.